Immune and Neural Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Deferoxamine Chelation Treatment
| العنوان: | Immune and Neural Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Deferoxamine Chelation Treatment |
|---|---|
| المؤلفون: | Antonia Taparkou, Miranda Athanassiou-Metaxa, Florendia Kanakoudi-Tsakalidou, Vassilios Perifanis, Dimitrios Zafiriou, Marina Economou, Natalie Tourkantoni, V Tzimouli |
| المصدر: | Hemoglobin. 32:35-40 |
| بيانات النشر: | Informa UK Limited, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, Iron Overload, Adolescent, Pyridones, T-Lymphocytes, Thalassemia, medicine.medical_treatment, Clinical Biochemistry, Splenectomy, Deferoxamine, Iron Chelating Agents, Gastroenterology, chemistry.chemical_compound, Immune system, Internal medicine, medicine, Humans, Immunologic Factors, Deferiprone, Chelation therapy, Child, Evoked Potentials, Genetics (clinical), Autoantibodies, B-Lymphocytes, business.industry, beta-Thalassemia, Biochemistry (medical), Autoantibody, Hematology, medicine.disease, Chelation Therapy, chemistry, Immune System, Ferritins, Immunology, Toxicity, Drug Therapy, Combination, business, medicine.drug |
| الوصف: | Deferiprone (L1), has previously been reported to be associated with immunological abnormalities in iron loaded thalassemia patients. However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO). During chelation therapy with DFO, several complications have been reported, which were due to pharmacological activity and high dose toxicity with regard to both acoustic and visual effects, as well as peripheral nerve disorders that were measured by nerve conduction velocities. The immune and neural status of 44 beta-thalassemic patients, aged 10-30 years (mean 19.4 +/- 4.9), receiving L1 as a monotherapy (n = 21), or in combination with DFO (n = 23), has been followed for 2 years by monitoring the level of immunoglobulins (IgG, IgM, IgA), the level of T and B lymphocytes (CD4/CD8), the auto antibodies: anti nuclear (ANA), anti-double-stranded (anti-ds DNA), anti reticulin (anti-R1), anti-extra nuclear (anti-ENA), anti histone (anti-AHA), anti liver-kidney-muscle (anti-LKM), anti-smooth muscle (anti-SMA), anti-thyroid (anti-ATA), anti-mitochondrial (anti-AMA) antibodies and the C-reactive protein. The percentage of patients with disorders of the immune and nervous system concerned very few cases. None of our patients with pathological findings in their immunological or neurophysiological examinations presented any signs or symptoms of involvement of the immune or nervous system. Further advantages have been identified for the oral use of L1 and its combination with DFO, including synergistic efficacy and lower dosing with limited toxicity. |
| تدمد: | 1532-432X 0363-0269 |
| DOI: | 10.1080/03630260701680631 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896427ce3300cd1899801147e57b45bc https://doi.org/10.1080/03630260701680631 |
| رقم الانضمام: | edsair.doi.dedup.....896427ce3300cd1899801147e57b45bc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1532432X 03630269 |
|---|---|
| DOI: | 10.1080/03630260701680631 |